Inovio CEO: Zika Vaccine Could Take a Few Years

The video discusses the development of a DNA-based vaccine for the Zika virus, highlighting the rapid progress from design to FDA approval for human testing. It explores the market potential and risks of being a first mover, the innovative technology used, and the role of the government in addressing the Zika virus. The video also compares Zika to other epidemics like Ebola, emphasizing the unique challenges it presents.

What are the expected infection rates of the Zika virus in the population by the end of the year?

What are the benefits of being a first mover in the vaccine development space?

How does the new vaccine technology differ from traditional methods?

What role could the US government play in addressing the Zika virus?

In what ways does Zika virus infection differ from Ebola?